PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ETHICS, PHARMACY”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 631 records · Page 35Linked to original sources

Integrated patient-specific model of pharmacy practice.

The deficiencies of traditional models for the provision of clinical pharmacy services are discussed, and a patient-specific model that integrates drug distribution and clinical pharmacy functions is proposed. Traditional models have either designated specific individuals as providers of clinical pharmacy services or have combined distributive and supportive services with clinical services. In both cases, clinical services have been of secondary importance. Such models have resulted in inconsistent clinical services for which the patient is not necessarily the primary focus and have made it difficult for pharmacists to understand their mission. The lack of a well-defined primary clinical role for pharmacists has confused health-care providers and created problems for managers attempting to evaluate pharmacists and justify clinical services. The integrated patient-specific model is based on the ethical imperative that the patient must be central to any health-care endeavor. Under this model, clinical pharmacy services are of central importance and distributive services are integrated as a secondary but still very important aspect of comprehensive institutional pharmacy services. Critical elements of the integrated model include a patient-centered philosophy of practice, a definition of clinical pharmacy work, and a managerial framework. The integrated patient-specific model of pharmacy practice puts pharmacists in a professional relationship with patients and explicitly defines clinical services and priorities.

Institutional Practice↗

Research and development of drugs and biologic entities.

Uses of and problems associated with the products of biotechnology are described, and implications of the new technology for pharmacy practice and education are outlined. Biotechnology is the application of biological processes to the generation of new therapeutic and diagnostic drug products and vaccines. More than 100 biotechnology products are under development in the United States. Sixteen products, including 13 therapeutic agents and three vaccines, have been marketed. The largest category of biotechnology products now in development is monoclonal antibodies; nearly half of these are targeted for cancer therapy. The second largest group of agents undergoing clinical trials is vaccines. Showing particular promise are products such as colony-stimulating factors and growth factors, which may offer therapy for conditions that are currently untreatable. Problems intrinsic to the products of biotechnology include their short half-lives, difficulties associated with delivering the product in a timely fashion to a specific site, and, in the case of vaccines, the ability of the target organisms to change their structure. Ethical and economic considerations complicate decisions facing those concerned with the rational use of these products. Preparing pharmacy students and practitioners to take a lead role in the use of the products of biotechnology will require substantial modifications in pharmacy education and training at all levels. While some schools of pharmacy have instituted major curriculum revisions to accommodate such needs, others have yet to respond to the challenge of biotechnology. Biotechnology offers increasing opportunities for pharmacists to take an active role in therapeutic decision making, drug delivery, and the education of their health-care colleagues and of patients.

Biotechnology↗

[Criminology in biomedical research].

Fraud in biomedical research is far more frequent than detected and published. The author discusses the essence of fraud in research, the causes why data of medical investigations are falsified citing some interesting examples from the literature. Difficulties and consequences of detecting scientific misconduct and possible mechanisms to avoid false results to be published are mentioned.

Animals↗

Achieving excellence.

The concept of achieving excellence in pharmacy through development of effective leadership is discussed. The majority of hospital pharmacy directors have had very little education and training in management and effective leadership. Yet, excellent leadership skills will be needed to transform pharmacy more completely into a health profession. The management style most likely to be effective in this era of change is one that encompasses a high regard for both people and production through shared responsibility, high participation, involvement, and commitment. The following recommendations are offered to help achieve excellence through effective leadership: the ethic of self-development must be instilled in aspiring managers; courses in human behavior, leadership, and management should be added to undergraduate pharmacy curricula; pharmacy technicians should be educated in college-based programs that focus on drug distribution; Master of Science programs in hospital pharmacy should be deleted or restructured to focus on leadership and management; regional "centers for excellence" in leadership education should be developed; general residency training should be incorporated in undergraduate education so that more advanced residencies can be offered to graduates; high-level, self-study programs in management and leadership need to be developed, and substantial research funds need to be dedicated to the study of hospital pharmacy management.

Drug Industry↗

Content on end-of-life care in major pharmacy textbooks.

The quantity and quality of end-of-life-care (EOLC) information in commonly used pharmacy textbooks were studied. EOLC content in each of eight best-selling pharmacy textbooks was assigned to 1 of 13 domains; there were a total of 104 possible domains for all eight books. Every mention of EOLC was given a score of 2 for "helpful content present" or 1 for "minimal content present." The quantity of EOLC content was assessed by tabulating the raw number of entries. The average number of EOLC-related entries per book ranged from 1.0 (ethics) to 27.5 (natural history). Eighty-one domains (78%) had fewer than 10 entries, 66 (63%) had 5 or fewer entries, and 28 (27%) had 1 entry or none. The overall quality of content was low, especially in the domains of spiritual issues, ethics, and context of care. The results were consistent with findings for medicine and nursing textbooks. A review of eight commonly used pharmacy textbooks revealed inadequate coverage of EOLC.

Curriculum↗

Sildenafil and the Internet.

PURPOSE: The Internet is changing the way medicine is being practiced and challenging our notions of the doctor-patient relationship. We analyze the development of online prescriptions and propose guidelines for the sale of sildenafil over the Internet. MATERIALS AND METHODS: Using MEDLINE, Medscape and Lexis-Nexis search engines we reviewed pertinent materials from January 1996 to July 1999 focusing on the keywords Viagra, prescription and Internet. The review included press releases, law review articles, case law, medical literature, pending litigation, proposed legislation, and federal and state statutes. RESULTS: Online prescriptions are an outgrowth of the mail order drug business. This development continues the historic innovations in communications and transportation that have enabled physicians to practice medicine over long distances while maintaining ties to hospitals and other specialists. While the sale of sildenafil over the Internet may be profitable and convenient, it raises a variety of legal, ethical and safety concerns. Many federal and state organizations have addressed the issue without establishing a clear standard. CONCLUSIONS: A clear distinction exists between online prescriptions and pharmacies. While it may be acceptable for sildenafil to be sold over the Internet given current technologies, it must be done within the confines of a traditional doctor-patient relationship. Online prescriptions must be limited to patients who live in states in which the prescribing physician is licensed. Failure to establish a doctor patient relationship in this context breeches ethical standards, and may give rise to potential civil and criminal liabilities.

Erectile Dysfunction↗

Supply of medicines: paternalism, autonomy and reality.

Radical changes are taking place in the United Kingdom in relation to the classification of, and access to, medicines. More and more medicines are being made available over the counter both in local pharmacies and in supermarkets. The provision of more open access to medicines may be hailed as a triumph for patient autonomy. This paper examines whether such a claim is real or illusory. It explores the ethical and legal implications of deregulating medicines. Do patients benefit? What is the impact on pharmacists? Are the true beneficiaries of change largely the pharmaceutical industries?

Beneficence↗

[History of professionalization of modern clinical pharmacist (1): pharmaceutical practices in hospice before the French Revolution].

The times around the French Revolution, as E. H. Ackerknecht pointed out, were especially epochmaking in that "the clinical medicine" or 'medicine in the hospital' was born and bred through the days by discarding the medicine of court physicians and the metaphysical medicine that had been dominant for centuries until then. This change is, therefore, very important from the viewpoints of sociopolitical, cultural and medical histories. The medicine practised and taught mainly in Paris in those days based politically on the newborn nationalistic centralization; technically on pathologicoanatomy and biostatistics; and conceptually on the modern medical epistemologoy that made it possible to abstract and see a 'disease' from the sick by observation, description and classification of their common signs and symptoms, and then to ignore a suffering specific to each individual patient instead. Thus those who could believe in the être (entity) of a 'disease' the clinical medicine made it 'visible' were trained for medical professionals such as modern physicians, surgeons and clinical pharmacists, which finally realized the professional monopolization of the medicine. The aim of this paper is to report and analyze the historical process how there came out the modern clinical pharmacist who was permitted by the nation as the only occupation to deal in ethical drugs in the hospital, while excluding many other people who had been treating 'traditional medicines' from the modern pharmacies of hospitals.

Clinical Medicine↗

Digital twins in precision pharmacotherapy: emerging applications, challenges, and future directions.

Digital twin technology, defined as dynamic digital models that represent individual patients, is emerging as a promising paradigm in precision pharmacotherapy. The integration of pharmacokinetic and pharmacodynamic (PK/PD) modeling, clinical data, genomic information, and real-time patient monitoring enables digital twins to shift drug therapy away from population-based averages toward individualized, adaptive decisions. This narrative review explores conceptual frameworks, emerging applications, methodological approaches, clinical value, limitations, and future directions of digital twins in pharmacotherapy, with particular emphasis on the role of clinical pharmacists. Unlike broader digital twin reviews that primarily emphasize technical architectures, disease-specific applications, or pharmaceutical research and development, this review focuses on the clinical-pharmacy translation layer: how digital twin outputs can be interpreted, validated, communicated, and converted into actionable medication decisions at the bedside and across ambulatory care settings. Key applications include precision dosing, polypharmacy management, antimicrobial stewardship, and the optimization of complex therapies, alongside important ethical, regulatory, and implementation challenges.

clinical pharmacy↗

"Talking about drug treatments--who should say what to whom?"--the second DTB symposium.

Information about medicines is as important as the quality of the medicines themselves. Without sufficient, accurate and understandable information the doctor cannot decide on the best treatment regimen to offer and ultimately the patient cannot decide what treatment to accept. The second annual Drug and Therapeutics Bulletin symposium, held in March, considered the provision of information, its production and distribution, and the legal, ethical and professional codes by which it is shaped. These issues were addressed by Ian Dodds-Smith (legal aspects), Nick Barber (pharmacy matters), Bonnie Sibbald (communication between hospital and general practice), Barbara Altounyan (the media), David Dickinson and Marianne Rigge (consumers), Gwen Parr and Justin Greenwood (the pharmaceutical industry) and Joe Collier (provision of consensus advice). The audience also made important contributions.

Advertising↗

Developing performance-appraisal systems.

The development and applications of performance-appraisal systems for hospital pharmacy personnel are discussed. The need for a performance-appraisal system is explained from the perspectives of the employee, the manager, and the hospital. Ethical standards that should be considered by managers during the appraisal process are listed. Performance standards are a key component of a performance-appraisal system and should be developed jointly by management and staff. Types of appraisal methods, personnel who should conduct appraisals, and the frequency at which appraisals should be conducted are discussed. Potential biases in appraisal methods and the preparation for and conduct of employee appraisals are discussed. A performance-appraisal system should be designed to meet the needs of employees, managers, and the hospital. Such a system will be more effective if it ensures the regular, frequent flow of data on employee performance, the systematic comparison of these data with previously agreed-upon expectations, and the frequent reporting of the results of these comparisons to both employees and managers.

Employee Performance Appraisal↗